Recent advances on the pathogenesis of Huntington's disease

Experimental Neurology

Volumn 157, Issue 1, 1999, Pages 1-18

  Petersén, Åsa ^a   Mani, Kevin ^a   Brundin, Patrik ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Excitotoxicity; Huntingtin; Huntington's disease; Neuropathology; Pathogenesis; Striatum; Transg enic disease model

Indexed keywords

CALMODULIN; CASPASE; HUNTINGTIN; UBIQUITIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; ENERGY METABOLISM; GABAERGIC TRANSMISSION; GENE EXPRESSION REGULATION; GENETIC CODE; HUNTINGTON CHOREA; MOUSE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; REVIEW; TRANSGENIC ANIMAL;

EID: 0032912386     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1998.7006     Document Type: Review

References (168)

1. Albin R. L., Tagle D. A. Genetics and molecular biology of Huntington's disease. Trends Neurosci. 18:1995;11-14.
2. Alexi T., Hughes P. E., Faull R. L., Williams C. E. 3-Nitroproprionic acid's lethal triplet: Cooperative pathways of neurodegeneration. Neuroreport. 9:1998;R57-R64.
3. Ambrose C. M., Duyao M. P., Barnes G., Bates G. P., Lin C. S., Srinidhi J., Baxendale S., Hummerich H., Lehrach H., Altherr M., Wasmuth J., Buckler A., Church D., Housman D., Berks M., Micklem G., Durbin R., Dodge A., Read A., Gusella J., MacDonald M. E. Structure and expression of the Huntington's disease gene: Evidence against simple inactivation due to an expanded CAG repeat. Somat. Cell Mol. Genet. 20:1994;27-38.
4. Andrade M. A., Bork P. HEAT repeats in the Huntington's disease protein. Nature Genet. 11:1995;115-116.
5. Andrew S. E., Goldberg Y. P., Kremer B., Telenius H., Theilmann J., Adam S., Starr E., Squitieri F., Lin B., Kalchman M. A., Graham R. K., Hayden M. R. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nature Genet. 4:1993;398-403.
6. Ankarcrona M., Dypbukt J. M., Bonfoco E., Zhivotovsky B., Orrenius S., Lipton S. A., Nicotera P. Glutamate-induced neuronal death: A succession of necrosis or apoptosis depending on mitochondrial function. Neuron. 15:1995;961-973.
7. Ankarcrona M., Dypbukt J. M., Orrenius S., Nicotera P. Calcineurin and mitochondrial function in glutamate induced neuronal apoptosis. FEBS Lett. 394:1996;321-324.
8. Aronin N., Chase K., Young C., Sapp E., Schwarz C., Matta N., Kornreich R., Landwehrmeyer B., Bird E., Beal M. F., Vonsattel J.-P., Smith T., Carraway R., Boyce F. M., Young A. B., Penney J. B., DiFiglia M. CAG expansion affects the expression of mutant huntingtin in the Huntington's disease brain. Neuron. 15:1995;1193-1201.
9. Arzberger T., Krampel K., Leimgruber S., Weindl A. Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease-An in situ hybridization study. J. Neuropathol. Exp. Neurol. 56:1997;440-454.
10. Ashizawa T., Wong L.-J. C., Richards C. S., Caskey C. T., Jankovic J. CAG repeat size and clinical presentation in Huntington's disease. Neurology. 44:1994;1137-1143.
11. Augood S. J., Faull R. L., Emson P. C. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann. Neurol. 42:1997;215-221.
12. Bao J., Sharp A. H., Wagster M. V., Becher M., Schilling G., Ross C. A., Dawson V. L., Dawson T. M. Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin. Proc. Natl. Acad. Sci. USA. 93:1996;5037-5042.
13. Beal M. F., Kowall N. W., Ellison D. W., Mazurek M. F., Swartz K. J., Martin J. B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 321:1986;168-171.
14. Beal M. F., Ferrante R. J., Swartz K. J., Kowall N. W. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J. Neurosci. 11:1989;1649-1959.
15. Beal M. F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses. Ann. Neurol. 31:1992;119-130.
16. Beal M. F., Brouillet E., Jenkins B., Henshaw R., Rosen B., Hyman B. T. Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J. Neurochem. 61:1993;1147-1150.
17. Beal M. F., Hyman B. T., Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases. Trends Neurosci. 16:1993;125-131.
18. Beal M. F. Aging, energy and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38:1995;357-366.
19. Becher M. W., Kotzuk J. A., Sharp A. H., Davies S. W., Bates G. P., Price D. L., Ross C. A. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions andIT15. Neurobiol. Dis. 4:1998;387-397.
20. Behrens M. I., Koh J., Canzoniero L. M., Sensi S. L., Csernansky C. A., Choi D. W. 3-nitroproprionic acid induces apoptosis in cultured striatal and cortical neurons. Neuroreport. 6:1995;545-548.
21. Block-Galarza J., Chase K. O., Sapp E., Vaughn K. T., Vallee R. B., DiFiglia M., Aronin N. Fast transport and retrograde movement of huntingtin and HAP1 in axons. Neuroreport. 8:1997;2247-2251.
22. Bots G. Th. A. M., Bruyn G. W. Neuropathological changes of the nucleus accumbens in Huntington's chorea. Acta Neuropathol. 55:1987;21-22.
23. Brandt J., Bylsma F. W., Gross R., Stine O. C., Ranen N., Ross C. A. Trinucleotide repeat length and clinical progression in Huntington's disease. Neurology. 46:1996;527-531.
24. Bredesen D. E. Neural apoptosis. Ann. Neurol. 38:1995;839-851.
25. Bredt D. S., Glatt C. E., Hwang P. M., Fotuhi M., Dawson T. M., Snyder S. H. Nitric oxide synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase. Neuron. 7:1991;615-624.
26. Burke J. R., Enghild J. J., Martin M. E., Jou Y.-S., Myers R. M., Roses A. D., Vance J. M., Strittmatter W. J. Huntingtin and DRPLA proteins selectively interact with the enzyme GADPH. Nature Med. 2:1996;347-349.
27. Butterworth N. J., Williams L., Bullock J. Y., Love D. R., Faull R. L., Dragunow M. Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum. Neuroscience. 87:1998;49-53.
28. Cammarata S., Caponnetto C., Tabaton M. Ubiquitin-reactive neurites in cerebral cortex of subjects with Huntington's chorea: A pathological correlate of dementia. Neurosci. Lett. 156:1993;96-98.
29. Cariello L., de Cristofaro T., Zanetti L., Cuomo T., Di Maio L., Campanella G., Rinaldi S., Zanetti P., Di Lauro R., Varrone S. Transglutaminase activity is related to CAG repeat length in patients with Huntington's disease. Hum. Genet. 98:1996;633-635.
30. Cha J. H., Kosinski C. M., Kerrer J. A., Alsdorf S. A., Mangiarini L., Davies S. W., Penney J. B., Bates G. P., Young A. B. Altered brain neurotransmittor receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc. Natl. Acad. Sci. USA. 95:1998;6480-6485.
31. Chase K. O., Sapp E., Laforet G., Lee H. S., McIntyre C., Cardigan B. A., Tagle D., Stein J. S., Boyce F. M., Aronin A., DiFiglia M. Neuroanatomical features of a transgenic model of Huntington's disease. Soc. Neurosci. Abstr. 1998;380.5.
32. Claes S., Van Zand K., Legius E., Dom R., Malfroid M., Baro F., Godderis J., Cassiman J. J. Correlations between triplet repeat expansion and clinical features in Huntington's disease. Arch. Neurol. 52:1995;749-753.
33. Colomer V., Engelender S., Sharp A. H., Duan K., Cooper J. K., Lanahan A., Lyford G., Worley P., Ross C. A. Huntingtin-associated protein 1 (HAP1) binds to a Trio-like polypeptide, with a rac1 guanine nucleotide exchange factor domain. Hum. Mol. Genet. 6:1997;1519-1525.
34. Coyle J. T., Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature. 263:1976;244-246.
35. Coyle J. T., Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 262:1993;689-695.
36. Davies S. W., Turmaine M., Cozens B. A., DiFiglia M., Sharp A. H., Ross C. A., Scherzinger E., Wanker E. E., Mangiarini L., Bates G. P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 90:1997;537-548.
37. Davies S. W., Beardsall K., Turmaine M., DiFiglia M., Aronin N., Bates G. P. Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions. Lancet. 351:1998;131-133.
38. Dawson T. M., Bredt D. S., Fotuhi M., Hwang P. M., Snyder S. H. Nitric oxide synthase and neuronal NADPH diaphorase are identical in brain and peripheral tissue. Proc. Natl. Acad. Sci. USA. 88:1991;7797-7801.
39. Dawson V. L., Dawson T. M., Bartley D. A., Uhl G. R., Snyder S. H. Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J. Neurosci. 13:1993;2651-2661.
40. Dawson V. L., Kizushi V. M., Huang P. L., Snyder S. H., Dawson T. M. Resistance to neurotoxicity in cortical cultures from neuronal nitric oxide synthase-deficient mice. J. Neurosci. 16:1996;2479-2487.
41. De Rooij K. E., Dorsman J. C., Smoor M. A., Den Dunnen J. T., Van Ommen G.-J. B. Subcellular localization of the Huntington's disease gene product in cell lines by immunofluorescence and biochemical subcellular fractionation. Hum. Mol. Genet. 5:1996;1093-1099.
42. Dickson D. W. Apoptosis in the brain. Am. J. Pathol. 146:1995;1040-1044.
43. DiFiglia M., Sapp E., Chase K., Schwarz C., Meloni A., Young C., Martin E., Vonsattel J-P., Carraway R., Reeves S. A., Boyce F. M., Aronin N. A. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron. 14:1995;1075-1081.
44. DiFiglia M., Sapp E., Chase K. O., Davies S. W., Bates G. P., Vonsattel J.-P., Aronin N. A. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 277:1997;1990-1993.
45. DiMauro S., Schon E. S. Mitochondrial DNA and diseases of the nervous system: The spectrum. Neuroscientist. 4:1998;53-63.
46. Doble A. Excitatory amino acid receptors and neurodegeneration. Therapie. 50:1995;319-337.
47. Dugan L. L., Sensi S. L., Canzoniero L. M., Handran S. D., Rothman S. M., Lin T.-S., Goldberg M. P., Choi D. W. Mitochondrial production of reactive oxygen species in cortical nertons following exposure toNd. J. Neurosci. 15:1995;6377-6388.
48. Duyao M. P., Auerbach A. B., Ryan A., Persichetti F., Barnes G. T., McNeil S. M., Ge P., Vonsattel J.-P., Gusella J. F., Joyner A. L., MacDonald M. E. Inactivation of the mouse Huntington's disease gene homologHdh. Science. 269:1995;407-410.
49. Dragunow M., Faull R. L., Lawlor P., Beilharz E. J., Singleton K., Walker E. B., Mee E. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. Neuroreport. 6:1995;1053-1057.
50. Engelender S., Sharp A. H., Colomer V., Tokito M. K., Lanahan A., Worley P., Holzbaur E. L., Ross C. A. Huntingtin-associated protein 1 (HAP1) interacts with the p150 Glued subunit of dynactin. Hum. Mol. Genet. 6:1997;2205-2212.
51. Farrer L. A., Conneally P. M., Yu P.-L. The natural history of Huntington's disease: Possible role of "aging genes." Am. J. Hum. Genet. 18:1984;115-123.
52. Farrer L. A., Cupples L. A., Kiely D. K., Conneally P. M., Myers R. H. Inverse relationship between age at onset of Huntington's disease and paternal age suggests involvement of genetic imprinting. Am. J. Hum. Genet. 50:1992;528-535.
53. Ferrante R. J., Kowall N. W., Beal M. F., Martin J. B., Bird E. D., Richardson E. P. Jr. Morphologic and histochemical characteristics of a spared subset of neurons in Huntington's disease. J. Neuropathol. Exp. Neurol. 46:1987;12-27.
54. Ferrante R. J., Gutekunst C. A., Persichetti F., McNeil S. M., Kowall N. W., Kowall J. F., Gusella J. F., MacDonald M. E., Beal M. F., Hersch S. M. Heterogenous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. J. Neurosci. 17:1997;3052-3063.
55. Fesus L., Thomazy V. Searching for function of tissue transglutaminase: Its possible involvement in biochemical pathway of programmed cell death. Adv. Expl. Biol. 231:1988;119-134.
56. Fujita K., Ando M., Yamauchi M., Nagata Y., Honda M. Alteration of transglutaminase activity in rat and human spinal cord after neuronal degeneration. Neurochem. Res. 20:1995;1195-1201.
57. Gavrieli Y., Sherman Y., Ben-Sasson S. A. Identification of programmed cell deathin situ. J. Cell Biol. 119:1992;493-501.
58. Gegelashvili G., Schousboe A. High affinity glutamate transporters: Regulation of expression and activity. Mol. Pharmacol. 52:1997;6-15.
59. Gerber H. P., Seipel K., Georgiev O., Höfferer M., Hug M., Rusconi S., Schaffner W. Transcriptional activation modulated by homopolymeric glutamine and proline stretches. Science. 263:1994;808-811.
60. Gerfen C. R. The neostriatal mosaic: Multiple levels of compartmental organization. Trends Neurosci. 15:1992;133-139.
61. Goldberg Y. P., Nicholson D. W., Rasper D. M., Kalchman M. A., Koide H. B., Graham R. K., Bromm M., Kazemi-Esfarjani P., Thornberry N. A., Vaillancourt J. P., Hayden M. R. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nature Genet. 13:1996;442-449.
62. Gonzalez-Zulueta M., Ensz L. M., Mukhina G., Lebovitz R. M., Zwacka R. M., Engelhart J. F., Oberley L. W., Dawson V. L., Dawson T. M. Manganese superoxide dismutase protects nNOS neurons from NMDA and nitric oxide-mediated neurotoxicity. J. Neurosci. 18:1998;2040-2055.
63. Gourfinkel-An I., Cancel G., Trottier Y., Devys D., Tora L., Lutz Y., Imbert G., Saudou F., Stevanin G., Agid Y., Brice A., Mandel J. L., Hirsch E. C. Differential distribution of the normal and mutated forms of huntingtin in the human brain. Ann. Neurol. 42:1997;712-719.
64. Grafton S. T., Mazziotta J. C., Pahl J. J., St. George-Hyslop P., Haines J. L., Gusella J., Hoffman J. M., Baxter L. R., Phelps M. E. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch. Neurol. 49:1992;1161-1167.
65. Greene J. C., Greenamyre J. T. Characterization of the excitotoxic potential of the reversible succinate dehydrogenase inhibitor malonate. J. Neurochem. 64:1995;430-436.
66. Gu M., Gash M. T., Mann V. M., Javoy-Agid F., Cooper M., Schapira A. H. V. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 39:1996;385-389.
67. Gusella J. F., Wexler N. S., Conneally P. M., Naylor S. L., Anderson M. A., Tanzi R. E., Watkins P. C., Ottina K., Wallace M. R., Sakaguchi A. Y., Young A. B., Shoulsen I., Bonilla E., Martin J. B. A polymorphic DNA marker genetically linked to Huntington's disease. Nature. 306:1983;234-238.
68. Gusella J. F., MacDonald M. E., Ambrose C. M., Duyao M. P. Molecular genetics of Huntington's disease. Arch. Neurol. 50:1993;1157-1163.
69. Gutekunst C. A., Levey A. I., Heilman C. J., Whaley W. L., Yi H., Nash N. R., Rees H. D., Madden J. J., Hersch S. M. Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein anti-bodies. Proc. Natl. Acad. Sci. USA. 92:1995;8710-8714.
70. Hackam A. S., Wellington C. L., Hayden M. R. The fatal attraction of polyglutamine-containing proteins. Clin. Genet. 53:1998;233-242.
71. Hand D., Perry M. J., Haynes L. W. Cellular transglutaminases in neural development. Int. J. Dev. Neurosci. 11:1993;709-720.
72. Harper P. S. The epidemiology of Huntington's disease. Hum. Genet. 89:1992;365-376.
73. Hedreen J. C., Peyser C. E., Folstein S. E., Ross C. A. Neuronal loss in layer V and VI of cerebral cortex in Huntington's disease. Neurosci. Lett. 133:1991;257-261.
74. Hedreen J. C., Folstein S. E. Early loss of neostriatal striosome neurones in Huntington's disease. J. Neuropathol. Exp. Neurol. 54:1995;105-120.
75. Hodgson G., Agopvan N., Smith D., LePiane F., McCutcheon K., O'Kuskey J. R., Bissada N., Jamot L., Roder J., Rubin E. M., Hayden M. R. YAC transgenic mice expressing mutant human huntington show deficits in hippocampal long-term potentiation. Soc. Neurosci. Abstr. 1998;127.1.
76. Hoogeveen A. T., Willemsen R., Meyer N., de Rooij K. E., Roos R. A., van Ommen G. J., Galjaard H. Characterization and localization of the Huntington's disease gene product. Hum. Mol. Genet. 2:1993;2069-2073.
77. Hope B. T., Michael G. J., Knigge K. M., Vincent S. R. Neuronal NADPH diaphorase is a nitric oxide synthase. Proc. Natl. Acad. Sci. USA. 88:1991;2811-2814.
78. Huang Q., Zhou D., Sapp E., Aizawa H., Ge P., Bird E. D., Vonsattel J.-P., DiFiglia M. Quinolinic acid-induced increases in calbindin D28K immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease. Neuroscience. 65:1995;397-407.
79. Cell. 72:1993;971-983.
80. Jenkins B. G., Koroshetz W. J., Beal M. F., Rosen B. R. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology. 43:1993;2689-2695.
81. Jones A. L., Wood J. D., Harper P. S. Huntington's disease: Advances in molecular and cell biology. J. Inherit. Metab. Dis. 20:1997;125-138.
82. Kahlem P., Green H., Dijan P. Transglutaminase action imitates Huntington's disease: Selective polymerization of Huntingtin containing expanded polyglutamine. Mol. Cell. 1:1998;595-601.
83. Kalchman M. A., Graham R. K., Xia G., Koide H. B., Hodgson J. G., Graham K. C., Goldberg Y. P., Gietz R. D., Pickart C. M., Hayden M. R. Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J. Biol. Chem. 271:1996;19385-19394.
84. Kalchman M. A., Koide H. B., McCutcheon K., Graham R. K., Nichol K., Nishiyama K., Kazemi-Esfarjani P., Lynn F. C., Wellington C., Metzler M., Goldberg Y. P., Kanazawa I., Gietz R. D., Hayden M. R. HIP1,S. cerevisiae Sla2p, Nature Genet. 16:1997;44-53.
85. Kerr J. F., Wyllie A. H., Currie A. R. Apoptosis: A basic biological phenomenon with wide ranging implications in tissue kinetics. Br. J. Cancer. 26:1972;239-247.
86. Koh J.-Y., Peters S., Choi D. W. Neurons containing NADPH-diaphorase are selectively resistant to quinolinate toxicity. Science. 234:1986;73-76.
87. Koshy B., Matilla T., Burright E. N., Merry D. E., Fischbeck K. H., Orr H. T., Zoghbi H. Z. Spinocerbellar ataxia type-1 and spinobulbar muscular atrophy gene products interact with glyceraldehyde-3-phosphate dehydrogenase. Hum. Mol. Genet. 5:1996;1311-1318.
88. Kowall N. W., Ferrante R. J., Martin J. B. Patterns of cell loss in Huntington's disease. Trends Neurosci. 10:1987;24-29.
89. Krawczak M., Bockel B., Sandkuijl L., Thies U., Fenton I., Harper P. S. Covariate-dependent age-at-onset distributions for Huntington's disease. Am. J. Hum. Genet. 49:1991;735-745.
90. Kremer B., Tallaksen-Greene S. J., Albin R. L. AMPA and NMDA binding sites in the hypothalamic lateral tuberal nucleus: Implications for Huntington's disease. Neurology. 43:1993;1593-1595.
91. Kremer H. P., Roos R. A., Dingjan G., Marani E., Bots G. T. Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's Disease. J. Neuropathol. Exp. Neurol. 49:1990;371-382.
92. Kremer H. P. H., Roos R. A. C. Weight loss in Huntington's disease. Arch. Neurol. 49:1992;349.
93. Kuwert T., Lange H. W., Langen K. J., Herzog H., Aulich A., Feinendegen L. E. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain. 113:1990;1405-1423.
94. Laforet G. A., Lee H. S., Cadigan B., Chang P., Chase K. O., Sapp E., Martin E. M., McIntyre C., Williams M., Reddy P. H., Tagle D., Stein J. S., Boyce F. M., DiFiglia M., Aronin N. Development and characterization of a novel transgenic model of Huntington's disease which recapitulates features of the human illness. Soc. Neurosci. Abstr. 1998;380.8.
95. Leist M., Nicotera P. Apoptosis, excitotoxicity, and neuropathology. Exp. Cell Res. 239:1998;183-201.
96. Levine M. S., Chesselet M.-F., Koppel A., Gruen E., Cepada C., Carpenter E. M., Zanjani H., Hurst R. S., Altenus K. L., Murai J. S., Efstratiadis A., Zeitlin S. Enhanced sensitivity to glutamate receptor activation in mouse models of Huntington's disease. Soc. Neurosci. Abstr. 1998;380.7.
97. Li S. H., Li X. J. Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats. Hum. Mol. Genet. 7:1998;777-782.
98. Li X.-J., Li S.-H., Sharp A. H., Nucifora F. C. Jr., Schilling G., Lanahan A., Worley P., Snyder S. H., Ross C. A. A huntingtin-associated protein enriched in brain with implications for pathology. Nature. 378:1995;398-402.
99. Li X.-J., Sharp A. H., Li S.-H., Dawson T. M., Snyder S. H., Ross C. A. Huntingtin-associated protein (HAP1): Discrete neuronal localizations in the brain resemble those of neuronal nitric oxide synthase. Proc. Natl. Acad. Sci. USA. 93:1996;4839-4844.
100. Lipton S. A., Choi Y.-B., Pan Z.-H., Lei S. Z., Chen H.-S. V., Sucher N. J., Loscalzo J., Singel D. J., Stamler J. S. A redox-based mechanism for neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature. 364:1993;626-632.
101. Lipton S. A., Rosenberg P. A. Excitatory amino acids as a final common pathway for neurological disorders. N. Engl. J. Med. 330:1994;613-622.
102. Ludolph A. C., He F., Spencer P. S., Hammerstad J., Sabri M. 3-Nitropropionic acid-exogenous animal toxin and possible human striatal toxin. Can. J. Neurol. Sci. 18:1991;492-498.
103. MacDonald M. E., Gusella J. F. Huntington's disease: Translating a CAG repeat into a pathogenetic model. Curr. Opin. Neurobiol. 6:1996;638-643.
104. MacMillan J., Quarrell O. The neurobiology of Huntington's disease. Huntington's Disease. 1996;Saunders, The University Press, Cambridge. p. 317-358.
105. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S. W., Bates G. P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 87:1996;493-506.
106. Mangiarini L., Sathasivam K., Mahal A., Mott R., Seller M., Bates G. P. Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation. Nature Genet. 15:1997;197-200.
107. Manzoni O., Prezeau L., Marin P., Deshager S., Bockaert J., Fagni L. Nitric oxide-induced blockade of NMDA receptors. Neuron. 8:1992;653-662.
108. Matthews R. T., Ferrante R. J., Jenkins B. G., Browne S. E., Goetz K., Berger S., Chen I. Y.-C., Beal M. F. Iodoacetate produces striatal excitotoxic lesions. J. Neurochem. 69:1997;285-289.
109. McGeer E. G., McGeer P. L., Singh K. Kainate-induced degeneration of neostriatal neurons: Dependency upon corticostriatal tract. Brain Res. 139:1978;381-383.
110. McLaughlin B. A., Nelson D., Silver I. A., Erecinska M., Chesselet M.-F. Methylmalonate toxicity in primary neuronal cultures. Neuroscience. 86:1998;279-290.
111. McNeil S. M., Novelletto A., Srinidhi J., Barnes G., Kornbluth I., Albuth M. R., Wasmuth J. J., Gusella J. F., MacDonald M. E., Myers R. H. Reduced penetrance of the Huntington's disease mutation. Hum. Mol. Genet. 6:1997;775-779.
112. Metzler M., Nichol K., Reiner P. B., Hayden M. R. Conditional inactivation of huntingtin in transgenic mice. Soc. Neurosci. Abstr. 1998;380.4.
113. Monaghan D. T., Bridges R. J., Cotman C. W. The excitatory amino acid receptors: Their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu. Rev. Pharmacol. Toxicol. 29:1989;365-402.
114. Monckton D. G., Caskey C. T. Unstable triplet repeat diseases. Circulation. 91:1995;513-520.
115. Morris M., Scourfield J. Psychiatric aspects of Huntington's disease. Harper P. Huntington's Disease. 1996;73-122 SaundersThe University Press, Cambridge.
116. Nakao N. Protection of Striatal and Nigral Neurons by Trophic and Antioxidant Mechanisms: A Study on in Vitro and in Vivo Brain Insult Models and Neural Transplants. 1996;Wallin & Dalholm, Lund.
117. Nakao N., Brundin P. Effects of alpha-phenyl-tert. Neuroscience. 76:1997;749-761.
118. Nasir J., Floresco S. B., O'Kuskey J. R., Diewert V. M., Richman J. M., Zeisler J., Borowski A., Marth J. D., Philips A. G., Hayden M. R. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell. 81:1995;811-823.
119. Nicholson D. W., Thornberry N. A. Caspases: Killer proteins. Trends Biochem. Sci. 22:1997;299-306.
120. Nishiyama K., Kwak S., Takekoshi S., Watanabe K., Kanazawa I. In sity end-labeling detects necrosis of hippocampal pyramidal cells induced by kainic acid. Neurosci. Lett. 212:1996;139-142.
121. Novelli A., Reilly J. A., Lysko P. G., Henneberry R. C. Glutamate becomes neurotoxic via theNd. Brain Res. 451:1988;205-212.
122. Olney J. W. Brain lesion, obesity and other disturbances in mice treated with monosodium glutamate. Science. 164:1969;719-721.
123. Paulson H. L., Perez M. K., Trottier Y., Trojanowski J. Q., Subramony S. H., Das S. S., Vig P., Mandel J.-L., Fischbeck K. H., Pittman R. N. Intranuclear inclusions of expanded polyglutamine protein in spinocerbellar ataxia type 3. Neuron. 19:1997;333-344.
124. Portera-Cailliau C., Hedreen J. C., Price D. L., Koliatsos V. E. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J. Neurosci. 15:1995;3775-3787.
125. Perutz M. F., Johnson T., Suzuki M., Finch J. T. Glutamine repeats as polar zippers: Their possible role in inherited neurodegenerative diseases. Proc. Natl. Acad. Sci. USA. 91:1994;5355-5358.
126. Quarrell O., Harper P. The clinical neurology of Huntington's disease. Harper P. Huntington's Disease. 1996;31-72 SaundersThe University Press, Cambridge.
127. N. Am. J. Hum. Genet. 57:1995;593-602.
128. Reiner A., Albin R. L., Andersson K. D., D'Amato C. J., Penney J. B., Young A. B. Differential loss of striatal projection neurons in Huntington's disease. Proc. Natl. Acad. Sci. USA. 85:1988;5733-5737.
129. Ridley A. J. Rho: Theme and variations. Curr. Biol. 6:1996;1256-1264.
130. Robbins A. R., Ward R. D., Oliver C. A mutation in glyceraldehyde-3-phosphate dehydrogenase alters endocytosis in CHO cells. J. Cell Biol. 130:1995;1093-1104.
131. Roizin L., Stellar S., Liu J. C. Neuronal nuclear-cytoplasmic changes in Huntington's chorea: Electron microscope investigations. Chase T. N., Wexler N. S., Barbeau A. Advances in Neurology, Vol. 23, Huntington's Disease. 1979;95-122 Raven Press, New York.
132. Ross R. A. C., Bots G. Th. A. M. Nuclear membrane indentations in Huntington's chorea. J. Neurol. Sci. 61:1983;31-47.
133. Ross C. A. When more is less: Pathogenesis of glutamine repeat neurodegenerative diseases. Neuron. 15:1995;493-496.
134. Ross C. A. Intranuclear neuronal inclusions: A common pathogenetic mechanism for glutamine-repeat neurodegenerative diseases. Neuron. 19:1997;1147-1150.
135. Sanberg P. R., Fibiger H. C., Mark R. F. Body weight and dietary factors on Huntington's disease patients compared with matched controls. Med. J. Aust. 1:1981;407-409.
136. Sapp E., Schwarz C., Chase K., Bhide P. G., Young A. B., Penney J., Vonsattel J. P., Aronin N., DiFiglia M. Huntingtin localization in brains of normal and Huntington's disease patients. Ann. Neurol. 42:1997;604-612.
137. Scherzinger E., Lurz R., Turmaine M., Mangiarini L., Hollenbach B., Hasenbank R., Bates G. P., Davies S. W., Lehrach H., Wanker E. E. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell. 90:1997;549-558.
138. Schoepp D. D., Sacaan A. I. Metabotropic glutamate receptors and neuronal degenerative disorders. Neurobiol. Aging. 15:1994;261-263.
139. Schulz J. B., Henshaw D. R., Siwek D., Jenkins B. G., Ferrnate R. J., Cipolloni P. B., Kowall N. W., Rosen B. R., Beal M. F. Involvement of free radicals in excitotoxicityin vivo. J. Neurochem. 64:1995;2239-2247.
140. Seaton T. A., Copoper J. M., Schapira A. H. Free radicals scavengers protect dopaminergic cell lines from apoptosis by complex I inhibitors. Brain Res. 777:1997;110-118.
141. Seto-Oshima A., Emson P. C., Lawson E., Mountjoy C. Q., Carrasco L. H. Loss of matrix calcium-binding protein-containing neurons in Huntington's disease. Lancet. 4:1988;1252-1255.
142. Sharp A. H., Loev S. J., Schilling G., Li S.-H., Li X.-J., Bao J., Wagster M. V., Kotzuk J. A., Steiner J. P., Lo A., Hedreen J., Sisodia S., Snyder S. H., Dawson T. M., Ryugo D. K., Ross C. A. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron. 14:1995;1065-1074.
143. Sharp A. H., Ross C. A. Neurobiology of Huntington's disease. Neurobiol. Dis. 3:1996;3-15.
144. Sheline C. T., Choi D. W. Neuronal death in cultured murine cortical cells is induced by inhibition of GAPDH and triosephosphate isomerase. Neurobiol. Dis. 5:1998;47-54.
145. Skulachev V. P. Why are mitochondria involved in apoptosis? Permeability transition pores and apoptosis as selective mechanisms to eliminate superoxide-producing mitochondria and cell. FEBS Lett. 397:1996;7-10.
146. Snell R. G., MacMillan J. C., Cheadle J. P., Fenton I., Lazarou L. P., Davies P., MacDonald M. E., Gusella J. F., Harper P. S., Shaw D. J. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nature Genet. 4:1993;393-397.
147. Strong T. V., Tagle D. A., Valdes J. M., Elmer L. W., Boehm K., Swaroop M., Kaatz K. W., Collins F. S., Albin R. L. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nature Genet. 5:1993;259-265.
148. Susin S. A., Zamzami N., Castedo M., Hirsch T., Marchetti P., Macho A., Daugas E., Geuskens M., Kroemer G. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J. Exp. Med. 184:1996;1331-1341.
149. Telenius H., Kremer B., Goldberg Y. P., Theilmann J., Andrew S. E., Zeisler J., Adam S., Greenberg C., Ives E. J., Clarke L. A., Hayden M. R. Somatic and gonadal mosaicism of the Huntington's disease gene CAG repeat in brain and sperm. Nature Genet. 6:1994;409-414.
150. Tellez-Nagel I., Johnson B., Terry R. D. Studies on brain biopsies of patients with Huntington's chorea. J. Neuropathol. Exp. Neurol. 33:1974;308-332.
151. Thomas L. B., Gates D. J., Ritchfield E. K., O'Brien T. F., Schweitzer J. B., Steindler D. A. DNA end labeling (TUNEL) in Huntington's disease and other neuropathological conditions. Exp. Neurol. 133:1995;265-272.
152. Thornberry N. A., Lazebnik Y. Caspases: Enemies within. Science. 281:1998;1312-1316.
153. Trottier Y., Biancalana V., Mandel J.-L. Instability of CAG repeats in Huntington's disease: Relation to parental transmission and age of onset. J. Med. Genet. 31:1994;377-382.
154. Trottier Y., Devys D., Imbert G., Sandou F., An I., Lutz Y., Weber C., Agid Y., Hirsch E. C., Mandel J.-L. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nature Genet. 10:1995;104-110.
155. Tukamoto T., Nukina N., Ide K., Kanazawa I. Huntington's disease gene product, huntingtin, associates with microtubules in vitro. Mol. Brain Res. 51:1997;8-14.
156. Velier J., Kim M., Schwarz C., Kim T. W., Sapp E., Chase K., Aronin N., DiFiglia M. Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways. Exp. Neurol. 152:1998;34-40.
157. Vonsattel J. P. G., DiFiglia M. Huntington's disease. J. Neuropathol. Exp. Neurol. 57:1998;369-384.
158. Vuillaume I., Vermersch P., Destee A., Petit H., Salbonniere B. Genetic polymorphisms adjacent to the CAG repeat influence clinical features at onset in Huntington's disease. J. Neurol. Neurosurg. Psychiatry. 64:1998;758-762.
159. 33. Exp. Neurol. 127:1994;70-75.
160. Wanker E. E., Rovira C., Scherzinger E., Hasenbank R., Wälter S., Tait D., Colicelli J., Lehrach H. HIP-1: A huntingtin interacting protein isolated by the yeast two-hybrid system. Hum. Mol. Genet. 6:1997;487-495.
161. Weeks R. A., Piccini P., Harding A. E., Brooks D. J. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann. Neurol. 40:1996;49-54.
162. Wellington C. L., Brinkman R. R., O'Kuskey J. R., Hayden M. R. Toward understanding the molecular pathology of Huntington's disease. Brain Pathol. 7:1997;979-1002.
163. Wexler N. S., Young A. B., Tanzi R. E., Travers H., Starosta-Rubinstein S., Penney J. B., Snodgrass S. R., Shoulson I., Gomez F., Ramos Arroyo M. A., Penchaszadeh G. K., Moreno H., Gibbons K., Faryniarz A., Hobbs W., Anderson M. A., Bonilla E., Conneally P. M. Homozygotes for Huntington's disease. Nature. 326:1987;194-197.
164. Wyllie A. H. Cell death: A new classification separating apoptosis from necrosis. Bowen I. D., Lockshin R. A. Cell Death in Biology and Pathology. 1981;9-34 Chapman and Hall, New York.
165. Young A. B., Greenamyre J. T., Hollingsworth Z., Ablin R., D'Amato C., Shoulson I., Penney J. B. NMDA receptor losses in putamen from patients with Huntington's disease. Science. 241:1988;981-983.
166. Yuan J., Shaham S., Ledoux S., Ellis H. M., Horvitz H. R. TheC. elegans. Cell. 75:1993;641-652.
167. Zamzami N., Hirsch T., Dallaporta B., Petit P. X., Kroemer G. Mitochondrial implication in accidental and programmed cell death: Apoptosis and necrosis. J. Bionerg. Biomembr. 29:1997;185-193.
168. Zeitlin S., Liu J.-P., Chapman D. L., Papaioannou V. E., Efstratiadis A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nature Genet. 11:1995;155-163.